Published on 11 Jan 2018:

Recently, Meticulous Research® has published a comprehensive report on the “Cardiac Pacemaker Devices Market- Global Opportunity Analysis and Industry Forecast (2017-2022)”. According to Meticulous Research® estimates, the global cardiac pacemaker devices market is projected to reach USD 4,629.3 million by 2022.

There have been continued advancements and developments taken place in the cardiac pacemakers. The technology has advanced on many aspects such as with longer battery lives, smaller sized generators, and an intelligent ‘adaptive functionality’ closely emulating the human physiology. Despite these great technological advances over the last decades, the cardiac pacing was still associated with a significant rate of complications, mostly attributed to the pacing leads. Leads are susceptible to mechanical stress, whether transvenous or epicardial and constitute the pacing component most prone to failure.

The innovative leadless pacemakers help to overcome this issue and will most likely to be the future of cardiac pacing. Leadless pacing employs a single-chamber system to pace only the right ventricle and is fully self-contained, which eliminates the need for leads. These miniaturized systems are implanted using a transcatheter sheath and are indicated for patients who need right ventricular pacing only. These devices enable patients to avoid lead-related complications, from lead fracture to extraction challenges, as well as pocket-related complications such as infection and disfigurement. Leadless pacemakers are also likeminded with magnetic resonance imaging. Removing the lead component of the pacing system allows the patient to avoid lead-related complications such as fractures, insulation breaches, venous thrombus obstructions, and leads crossing the tricuspid valve, which can induce tricuspid regurgitation.

According to the WHO, an estimated 17.7 million people died from CVDs in 2015, representing 31% of all global deaths in a year. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. Cardiovascular disease remains the leading cause of death in the world and approximately 80% of all cardiovascular-related deaths occur in low-and-middle-income countries (LIMIC) and at a younger age in comparison to high-income countries. Developing societies are facing a hostile cardiovascular environment, characterized by changes in diet, the effects of tobacco, socioeconomic stressors, and economic constraints at both the national and personal level in addition to exposure to potential novel risk factors and perhaps a genetic or programmed fetal vulnerability to CVD in later life. Despite the tremendous progress in cardiac surgery, diminished long-term survival remains a major concern in adults with congenital heart disease (CHD). In this population, sudden cardiac death (SCD) is the most common cause of mortality.

Thus, rising prevalence of cardiovascular diseases, changing lifestyles, increasing obesity rate, increasing the burden of hypertension, and excessive consumption of alcohol and tobacco which leads to precipitate the risk of cardiovascular diseases in young population across the world increases the need for sophisticated and reliable devices and technologies to help control life-threatening arrhythmias. The rising incidence of cardiovascular diseases in younger population demands the innovative products with small size, longer product life, and lower side effects which would propel the adoption of advanced leadless pacemakers in the next few years.

The Cardiac Pacemaker Devices market study, published by Meticulous Research®, can be accessed at: “Cardiac Pacemaker Devices Market- Global Opportunity Analysis and Industry Forecast (2017-2022)”.